These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867 [Abstract] [Full Text] [Related]
3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593 [Abstract] [Full Text] [Related]
4. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736 [Abstract] [Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [Abstract] [Full Text] [Related]
9. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271 [Abstract] [Full Text] [Related]
11. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M. Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149 [Abstract] [Full Text] [Related]